NanoString Technologies

NanoString, Brigham and Women’s Hospital collaborate

Thursday, October 9, 2014

NanoString Technologies, a Seattle, Wash.-based provider of life science tools for translational research and molecular diagnostic products, has signed a multi-year, multi-investigator research collaboration with Harvard-affiliated, Boston, Mass.-based Brigham and Women’s Hospital (BWH) to accelerate the translation of genomic biomarker discoveries into clinical cancer diagnostics. Using NanoString’s Elements reagents, assays will be developed to detect gene expression, copy number variations and fusions from a diverse range of tumor samples.

[Read More]

NanoString launches nCounter Dx Analysis System for U.S. market

Thursday, November 14, 2013

NanoString Technologies, a provider of life science tools for translational research and molecular diagnostic products, has announced the availability of the nCounter Dx Analysis System for high-complexity, CLIA-certified laboratories. The nCounter Dx Analysis System is the only platform 510(k) cleared by the FDA to run the Prosigna Prognostic Breast Cancer Gene Signature Assay. The FLEX configuration offered on the nCounter Dx Analysis System supports other translational research applications, and facilitates the ability of laboratories to develop their own assays.

[Read More]

NanoString raises $20 million in Series D financing

Monday, November 7, 2011

NanoString Technologies, a privately held provider of life science tools for translational research and developer of molecular diagnostics, has closed $20 million in a Series D round of equity financing. New investors include GE, BioMed Ventures and Henri Termeer, former chairman and CEO of Genzyme. All previous venture investors in NanoString also participated in the financing, including Clarus Ventures, Draper Fisher Jurvetson and OVP Venture Partners.

[Read More]